N
Naoko Yamane
Researcher at Kyowa Hakko Kirin Co., Ltd.
Publications - 33
Citations - 4748
Naoko Yamane is an academic researcher from Kyowa Hakko Kirin Co., Ltd.. The author has contributed to research in topics: Antibody & Fusion protein. The author has an hindex of 8, co-authored 33 publications receiving 4642 citations.
Papers
More filters
Journal ArticleDOI
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity.
Toyohide Shinkawa,Kazuyasu Nakamura,Naoko Yamane,Emi Shoji-Hosaka,Yutaka Kanda,Mikiko Sakurada,Kazuhisa Uchida,Hideharu Anazawa,Mitsuo Satoh,Motoo Yamasaki,Nobuo Hanai,Kenya Shitara +11 more
TL;DR: The results indicate that the lack of fucosylation of IgG1 has the most critical role in enhancement of ADCC, although several reports have suggested the importance of Gal or bisecting GlcNAc and provide important information to produce the effective therapeutic antibody.
Patent
Method for controlling the activity of immunologically functional molecule
Nobuo Hanai,Kazuyasu Nakamura,Emi Shoji,Motoo Yamasaki,Kazuhisa Uchida,Toyohide Shinkawa,Susumu Imabeppu,Yutaka Kanda,Naoko Yamane,Hideharu Anazawa +9 more
TL;DR: A method for controlling the activity of an immunologically functional molecule such as an antibody, a protein or a peptide is described in this paper, where a promoter of the activity is defined.
Patent
Cells producing antibody compositions
Yutaka Kanda,Mitsuo Satoh,Kazuyasu Nakamura,Kazuhisa Uchida,Toyohide Shinkawa,Naoko Yamane,Emi Hosaka,Kazuya Yamano,Motoo Yamasaki,Nobuo Hanai +9 more
TL;DR: In this article, a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the anti-antibody or the like.
Patent
Antibody composition-producing cell
Yutaka Kanda,Mitsuo Satoh,Kazuyasu Nakamura,Kazuhisa Uchida,Toyohide Shinkawa,Naoko Yamane,Emi Hosaka,Kazuya Yamano,Motoo Yamasaki,Nobuo Hanai +9 more
TL;DR: In this article, a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the anti-antibody or the like.
Patent
Cells of which genome is modified
TL;DR: A cell in which genome is modified so as to have a more decreased or deleted activity of an enzyme relating to modification of a sugar chain in which 1position of fucose is bound to 6position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain than its parent cell, and a process for producing an antibody composition using the cell.